Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Plaque psoriasis Age: Adult |
Dose: Subcutaneous Injection – 300 mg Frequency: in 2 divided doses at weeks 0, 1, 2, 3, and 4, followed by monthly maintenance dosing Note: Review treatment if no response within 16 weeks of initial dose. |
|
Indication: Psoriatic arthritis Age: Adult Condition: With loading dose |
Dose: Subcutaneous Injection – 150 mg Frequency: at weeks 0, 1, 2, 3, and 4 and monthly thereafter Note: Review treatment if there is no response after 16 weeks. For patients with coexistent moderate to severe plaque psoriasis, use dosage and administration for plaque psoriasis. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Plaque psoriasis Age: 6 years and older |
Dose: Subcutaneous Injection – 75 mg Frequency: Weeks 0, 1, 2, 3, and 4, then every 4 weeks Note: Max Dose: 300 mg |
|
Indication: Plaque psoriasis Age: 6 years and older |
Dose: Subcutaneous Injection – 150 mg Frequency: Weeks 0, 1, 2, 3, and 4, then every 4 weeks Note: Max Dose: 300 mg |
Administration
- For subcutaneous injection
- Must be reconstituted before use
Side Effect
- Infections (28.7%)
- Nasopharyngitis (11.4-12.3%)
- Diarrhea (2.6-4.1%)
- URT infection (2.5-3.2%)
- Rhinitis (1.4%)
- Oral herpes (0.1-1.3%)
- Pharyngitis (1-1.2%)
- Urticaria (0.6-1.2%)
- Rhinorrhea (0.3-1.2%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Live vaccines
|
May enhance adverse effects and diminish therapeutic effect
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Active tuberculosis
|
Can worsen TB infection
|
|
Active hepatitis B
|
Can reactivate hepatitis
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Secukinumab Sensoready pens, prefilled syringes and vials must be refrigerated at 2ºC to 8ºC. Keep the product in the original carton to protect from light until the time of use. Do not freeze. To avoid foaming do not shake. Secukinumab does not contain a preservative; discard any unused portion.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.